Correction to “Efficacy and safety of curcumin in major depressive disorder: A randomized controlled trial”(Phytotherapy Research, (2013), 28, (579–585), 10.1002/ptr.5025);Efficacy and safety of curcumin in major depressive disorder: A randomized controlled trial

Phytotherapy Research

Volumn 28, Issue 4, 2014, Pages 579-585

  Sanmukhani, Jayesh ^a   Satodia, Vimal ^a   Trivedi, Jaladhi ^a   Patel, Tejas ^a   Tiwari, Deepak ^a   Panchal, Bharat ^a   Goel, Ajay ^b,c   Tripathi, Chandra Bhanu ^a  

^a GOVERNMENT MEDICAL COLLEGE   (India)

^b BAYLOR RESEARCH INSTITUTE   (United States)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

antidepressant; clinical trial simulations; CNS; curcumin; major depressive disorder

Indexed keywords

BCM 95; BENZODIAZEPINE DERIVATIVE; CURCUMIN; DEMETHOXYCURCUMIN; DIDEMETHOXYCURCUMIN; ESSENTIAL OIL; FLUNIL 20; FLUOXETINE; PARACETAMOL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTRITIS; HEADACHE; HOT FLUSH; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MOUTH ULCER; NAUSEA; PHOTOSENSITIVITY; RANDOMIZED CONTROLLED TRIAL;

ANIMALIA; CURCUMA LONGA; ZINGIBERACEAE;

ANTIDEPRESSANT; CLINICAL TRIAL SIMULATIONS; CNS; CURCUMIN; MAJOR DEPRESSIVE DISORDER;

ADULT; ANTIDEPRESSIVE AGENTS; CURCUMIN; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FLUOXETINE; HUMANS; MALE; MIDDLE AGED;

EID: 84898004438     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.8142     Document Type: Erratum

References (29)

1. American Psychiatric Association. 1994. Diagnostic and statistical manual of mental health disorders (4th ed). Washington DC.
2. Antony B, Merina B, Iyer VS, Judy N, Lennertz K, Joyal S,. 2008. A Pilot Cross-Over Study to Evaluate Human Oral Bioavailability of BCM-95CG (Biocurcumax), A Novel Bioenhanced Preparation of Curcumin. Indian J Pharm Sci 70: 445-449.
3. Cizza G,. 2011. Major depressive disorder is a risk factor for low bone mass, central obesity, and other medical conditions. Dialogues Clin Neurosci 13: 73-87.
4. Goel A, Jhurani S, Aggarwal BB,. 2008a. Multi-targeted therapy by curcumin: how spicy is it? Mol Nutr Food Res 52: 1010-1030.
5. Goel A, Kunnumakkara AB, Aggarwal BB,. 2008b. Curcumin as Curecumin: from kitchen to clinic. Biochem Pharmacol 75: 787-809.
6. Hamilton M,. 1960. A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-62.
7. Hartwig SC, Siegel J, Schneider PJ,. 1992. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm 49: 2229-2232.
8. Kulkarni S, Dhir A, Akula KK,. 2009. Potentials of curcumin as an antidepressant. ScientificWorldJournal 9: 1233-1241.
9. Kulkarni SK, Bhutani MK, Bishnoi M,. 2008. Antidepressant activity of curcumin: involvement of serotonin and dopamine system. Psychopharmacology (Berl) 201: 435-442.
10. Kulkarni SK, Dhir A,. 2009. Current investigational drugs for major depression. Expert Opin Investig Drugs 18: 767-788.
11. Lao CD, Ruffin MT, Normolle D, et al,. 2006. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 6: 10.
12. Lotufo-Neto F, Trivedi M, Thase ME,. 1999. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology 20: 226-247.
13. Mortimer AM,. 2007. Symptom rating scales and outcome in schizophrenia. Br J Psychiatry Suppl 50: s7-14.
14. Motterlini R, Foresti R, Bassi R, Green CJ,. 2000. Curcumin, an antioxidant and anti-inflammatory agent, induces heme oxygenase-1 and protects endothelial cells against oxidative stress. Free Radic Biol Med 28: 1303-1312.
15. Nutt DJ,. 2011. Highlights of the international consensus statement on major depressive disorder. J Clin Psychiatry 72: e21.
16. Raison CL, Miller AH,. 2011. Is Depression an Inflammatory Disorder? Curr Psychiatry Rep 13: 467-475.
17. Ruhe HG, Huyser J, Swinkels JA, Schene AH,. 2006. Dose escalation for insufficient response to standard-dose selective serotonin reuptake inhibitors in major depressive disorder: systematic review. Br J Psychiatry 189: 309-316.
18. Sharma RA, Euden SA, Platton SL, et al,. 2004. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 10: 6847-6854.
19. Singh S, Aggarwal BB,. 1995. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. J Biol Chem 270: 24995-25000.
20. Srimal RC, Dhawan BN,. 1973. Pharmacology of diferuloyl methane (curcumin), a non-steroidal anti-inflammatory agent. J Pharm Pharmacol 25: 447-452.
21. Thase ME, Pritchett YL, Ossanna MJ, Swindle RW, Xu J, Detke MJ,. 2007. Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder. J Clin Psychopharmacol 27: 672-676.
22. Ustun TB, Ayuso-Mateos JL, Chatterji S, Mathers C, Murray CJ,. 2004. Global burden of depressive disorders in the year 2000. Br J Psychiatry 184: 386-392.
23. Varalakshmi C, Ali AM, Pardhasaradhi BV, Srivastava RM, Singh S, Khar A,. 2008. Immunomodulatory effects of curcumin: in-vivo. Int Immunopharmacol 8: 688-700.
24. Walsh BT, Seidman SN, Sysko R, Gould M,. 2002. Placebo response in studies of major depression: variable, substantial, and growing. JAMA 287: 1840-1847.
25. Wang R, Xu Y, Wu HL, et al,. 2008. The antidepressant effects of curcumin in the forced swimming test involve 5-HT1 and 5-HT2 receptors. Eur J Pharmacol 578: 43-50.
26. Xia X, Cheng G, Pan Y, Xia ZH, Kong LD,. 2007. Behavioral, neurochemical and neuroendocrine effects of the ethanolic extract from Curcuma longa L. in the mouse forced swimming test. J Ethnopharmacol 110: 356-363.
27. Xu Y, Ku B, Cui L, et al,. 2007. Curcumin reverses impaired hippocampal neurogenesis and increases serotonin receptor 1A mRNA and brain-derived neurotrophic factor expression in chronically stressed rats. Brain Res 1162: 9-18.
28. Xu Y, Ku BS, Yao HY, et al,. 2005. The effects of curcumin on depressive-like behaviors in mice. Eur J Pharmacol 518: 40-46.
29. Yu ZF, Kong LD, Chen Y,. 2002. Antidepressant activity of aqueous extracts of Curcuma longa in mice. J Ethnopharmacol 83: 161-165.